Study: HPV cases drop by a third since vaccine programme
The human papillomavirus (HPV) immunisation programme has been successful in reducing HPV cases in young women in England.
Infection with HPV types 16 and 18 is responsible for 70-80% of cervical cancers.
However, a study conducted by Public Health England (PHE) has shown a reduction in these two types in sexually active young women since the vaccination programme was introduced.
Between 2010 and 2012, over 4000 samples were collected from young women receiving a chlamydia screen as part of the National Chlamydia Screening Programme in England.
Before the immunisation programme was introduced around one in five sexually active women aged 16 to 18 were infected with at least one of the two HPV types included in vaccines.
But since the introduction of the programme prevalence has dropped to one in 15 young women.
Post-immunisation prevalence of HPV types 16 and 18 infection was lowest among women aged 16 to 18 year old, the age group with the highest vaccination coverage.
Prior to the immunisation programme, this age group was shown to have the highest prevalence of infection.
David Mesher from Public Health England, presented the work at the Society for General Microbiology's Annual Conference.
He said: "This study provides an early indication that the national HPV immunisation programme is successfully reducing vaccine-type HPV infections in sexually active young women in England, and also suggests herd-immunity may be benefiting non-vaccinated young women and men.
"The data provide reassurance that the high efficacy against HPV infection in women reported in clinical trials can be effectively realised in practice, and in a programme achieving high coverage amongst young females. These data adds to our confidence that the HPV immunisation programme will achieve its aim of reducing cervical cancer."